Current News

April 26, 2017

Morphotek to Present its Proprietary RESPECT Antibody Drug Conjugate (ADC) Technology at the Upcoming 13th Annual PEGS Summit in Boston
Read More

April 3, 2017

Morphotek Launches Antibody Drug Conjugate Services Business
Read More

March 28, 2017

Morphotek to Present Three Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting 2017
Read More

March 22, 2017

Morphotek and Sandy Rollman Ovarian Cancer Foundation Launch Educational Resource on Clinical Trials
Read More

October 3, 2016

Morphotek and Eurofarma Laboratorios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America
Read More

September 13, 2016

Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center to Study Immunosuppressive Effects of Tumor Shed Antigens to Improve Future Patient Therapies
Read More

April 18, 2016

Morphotek Announces Publication of Phase 3 Results From MORAb-003-004 Trial in Platinum-Sensitive Ovarian Cancer Patients
Read More

March 31, 2016

Morphotek and AREVA Med to collaborate on Lead-212 Targeted Alpha Therapies
Read More

February 3, 2016

Morphotek Announces Collaboration with Mayo Clinic
Read More

December 16, 2015

Morphotek, Inc. Announces an Agreement With Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Mesothelin in Malignant Tissues
Read More

Displaying results 1-10 (of 128)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >| 

News & Events > News Archive